The NCRI Upper Gastrointestinal Group has four Study Groups that develop research in areas of strategic need.
The hepatobiliary workstream, chaired by Maria Hawkins.
Members:
Maria Hawkins, Professor in Radiation Oncology, UCL (subgroup chair)
Bristi Basu, Medical Oncologist, Academic Consultant in Experimental Cancer Therapeutics, University of Cambridge
David Bates, Professor in Oncology and Vascular Biology, University of Nottingham Centre for Cancer Sciences
Rebecca Brais, Consultant Histopathologist, Addenbrooke’s Hospital NHS Foundation Trust
John Bridgewater, Professor in Medical Oncology, UCL Cancer Institute
Saoirse Dolly, Clinical Fellow, Royal Marsden NHS Foundation Trust
Yo Green, Consumer Rep, National Cancer Research Group
Zaed Hamady, Cancer Surgeon, University Hospital Southampton NHS Foundation Trust
Timothy Kendall, Pathologist, University of Edinburgh
Shahid Khan, Consultant Gastroenterologist, Imperial College London
Yuk Ting Ma, Clinical Lecturer, King’s College London (KCL)
Hassan Malik, Consultant Hepatobiliary Surgeon and Clinical Lead of Digestive Surgery, University Hospital Aintree
Mairead Mcnamara, Honorary Consultant, Christie NHS Foundation Trust
Tim Meyer, Professor of Experimental Cancer Medicine, University College London (UCL)
Helen Morement, NCRI Consumer Forum member
Pam O’Donoghue, Lead GI Cancer Clinical Nurse Specialist, Harley Street Clinic
Kofi Oppong, Honorary Clinical Senior Lecturer, Newcastle University
Samir Pathak, Academic Clinical Lecturer/ Specialist registrar in HPB surgery, University Hospitals Bristol NHS Foundation Trust
John Primrose, Professor of Surgery, University of Southampton
Leonard Quinn, Hepatobiliary Research Fellow, Aintree University Hospital
Ganesh Radhakrishna, Consultant Clinical Oncologist, The Christie NHS Foundation Trust
Ian Rowe, Honorary Consultant Hepatologist, University of Leeds
Rohini Sharma, Consultant Medical Oncologist, Imperial College London
Juan Valle, Christie NHS Foundation Trust
Harpeet Wasan, Oncologist, Imperial College Healthcare NHS Trust – St Mary’s Hospital
Stephen Wigmore, Hepatobiliary-Pancreatic Surgical Services, University of Edinburgh
The neuroendocrine workstream, chaired by Dr Alan Anthoney, develops research into cancer of neuroendocrine cells, cells that release hormones into the bloodstream.
Members:
Alan Anthoney, Leeds Teaching Hospitals NHS Trust – Leeds General Infirmary (subgroup chair)
Cathy Bouvier, NET Patient Foundation
Martyn Caplin, University College London (UCL)
Daniel Cuthbertson, University of Liverpool
Lindsey Devlin, NET Patient Foundation
Andrea Frilling, Imperial College London
Ashley Grossman, Queen Mary University of London
Prakash Manoharan, Christie NHS Foundation Trust
Was Mansoor, Consultant in Medical Oncology, Christie NHS Foundation Trust
Mairead Mcnamara, Honorary Consultant, Christie NHS Foundation Trust
Alia Munir, Sheffield Teaching Hospitals NHS Foundation Trust
Neil Pearce, University Hospital Southampton NHS Foundation Trust
John Ramage, Hampshire Hospitals NHS Foundation Trust
Debashis Sarker, King’s College London (KCL)
Maia Sissons
Denis Talbot, Professor of Cancer Medicine, King’s College London (KCL)
Christina Thirlwell, King’s College London (KCL)
Jon Wadsley, Consultant Clinical Oncologist, Sheffield Teaching Hospitals NHS Foundation Trust
The oesophagogastric workstream, chaired by Dr Christopher Peters, develops research into cancer of the oesophagus and the stomach.
Members:
Christopher Peters, Clinical Senior Lecturer & Consultant Upper GI Surgeon, Imperial College London (subgroup chair)
Christopher Jones, Wellcome Trust Clinical Research Fellow; Honorary Specialty Registrar in Clinical Oncology, University of Leeds (subgroup assistant)
Anne Thomas, Medical Oncologist, University Hospitals of Leicester NHS Trust
Elizabeth Smyth, Clinical Research Fellow/ Consultant, Addenbrookes NHS Foundation Trust
Gareth Griffiths, Professor of Clinical Trials, Director of Southampton Clinical Trials Unit, University of Southampton
Heike Grabsch, Clinical Lecturer in Pathology, University of Leeds
Jeff Evans, Director of the Institute of Cancer Sciences, Beatson West of Scotland Cancer Centre
John Bradwell, NCRI Consumer, NCRI Consumer Forum
Naureen Starling, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust
Richard Turkington, Clinical Senior Lecturer, Queen’s University Belfast
Russell Petty, Clinical Professor of Molecular and Clinical Medicine, University of Dundee
Ruth Langley, Oncology and Clinical Trials, University College London (UCL)
Somnath Mukherjee, Consultant Clinical Oncologist, Cancer Research UK (CRUK) Oxford – Medical Research Council (MRC), Oxford Institute for Radiation Oncology
Thomas Crosby, Clinical Director and Consultant Clinical Oncologist, Velindre Cancer Centre
Tim Underwood, Professor of GI Surgery and Clinical Scientist, University of Southampton
William Allum, Royal Marsden NHS Foundation Trust
The NCRI Pancreatic Study Group of the NCRI Upper Gastrointestinal Group launched their strategic priorities in April 2023. They comprise a multi-disciplinary community of researchers and consumers focused on developing research to improve outcomes for cancer patients and identify areas of unmet need.
Please see the NCRI Pancreatic sub-group strategic priorities 2023-2026 for further information.
Working Group 1: Identification and testing of novel therapeutics
Working closely with the PrecisionPanc team, we will establish a new Novel Therapeutics working group to promote, design and implement signal-seeking trials testing novel therapeutics, which are essential to secure success of larger scale phase III trials aimed at establishing new standards of care.
Working Group 2: Exploration of novel perioperative therapies
Building on our early pancreatic cancer framework, the Perioperative Umbrella Working Group will develop a multi-arm platform study to test different neoadjuvant and adjuvant regimens and generate signals which might justify larger scale randomised trials. The group will also seek to write a position statement on what are the key outcome measures associated with neoadjuvant therapy.
Working Group 3: Evaluate precision radiotherapy
The Radiotherapy working group will initially focus on the role of SABR in locally advanced disease and oligometastases, as part of a framework study. The aim is to understand where Stereotactic ablative radiotherapy (SABR) sits by looking at outcomes including quality of life, cost effectiveness as well as predictive biomarkers/personalisation to differentiate patients with oligorecurrence and oligoprogression versus distant metastatic disease.
Working Group 4: Improve psychosocial and supportive care for pancreatic cancer patients
We propose to bring together a multidisciplinary working group with interest and expertise to scope what is needed to improve psychosocial and supportive care needs for pancreatic cancer patients and their families, potentially generating disease-specific tools for use in routine clinics.
The pancreatic workstream is chaired by Dr Pippa Corrie.
Members:
Pippa Corrie, Consultant medical oncologist, Addenbrooke’s Hospital NHS Foundation Trust (subgroup chair)
Thankamma Ajithkumar, Consultant Clinical Oncologist, Cambridge University Hospitals NHS Foundation Trust
Bristi Basu, Medical Oncologist, Academic Consultant in Experimental Cancer Therapeutics, University of Cambridge
Andrew Biankin, Director, University of Glasgow
John Bridgewater, Professor in medical oncology, UCL Cancer Institute
David Chang, Clinical Senior Lecturer in Surgery, Wolfson Wohl Cancer Research Centre, University of Glasgow
Jeff Evans, Director of the Institute of Cancer Sciences, Beatson West of Scotland Cancer Centre
Fieke Froeling, Consultant Medical Oncologist, University of Glasgow
Lesley Goodburn, Consumer Rep, National Cancer Research Institute (NCRI)
Richard Jackson, Senior Statistician, University of Liverpool
Nigel Jamieson, Senior Clinical Lecturer ,University of Glasgow
Hemant Kocher, Senior Lecturer & Consultant Surgeon, Barts and The London School of Medicine and Dentistry
Chris Macdonald, Head of Research, Pancreatic Cancer UK
Somnath Mukherjee, Consultant Clinical Oncologist, Cancer Research UK (CRUK) Oxford – Medical Research Council (MRC), Oxford Institute for Radiation Oncology
Eric O’Neill, CRUK/MRC Oxford Institute- Cell & Molecular Oncology (Onset & Therapy), University of Oxford
Daniel Palmer, University of Liverpool
Stephen Pereira, University College London (UCL)
David Propper, Consultant, Barts Health NHS Trust
Ganesh Radhakrishna, Consultant Clinical Oncologist -Gastrointestinal, Pancreatic, Oesophageal and hepaticopancreaticobiliary (HPB) cancers, Royal College of Radiologists
Keith Roberts, Queen Elizabeth Hospital Birmingham
Shivan Sivakumar, Academic Clinical Lecturer/ Honorary Speciality Registrar in Medical Oncology, University of Oxford
Karen Stead, Consumer Rep, National Cancer Research Institute (NCRI)
Juan Valle, Christie NHS Foundation Trust
Newton Wong, Consultant, University of Bristol